Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corcept Therapeutics 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 USA

P: 650-327-3270 F: 650-327-3218

Description:

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.

Key Statistics

Overview:

Market Capitalization, $K 2,880,010
Shares Outstanding, K 117,312
Annual Sales, $ 353,870 K
Annual Net Income, $ 106,010 K
Last Quarter Sales, $ 85,730 K
Last Quarter Net Income, $ 25,990 K
60-Month Beta 0.87
% of Insider Shareholders 16.40%
% of Institutional Shareholders 71.01%
Float, K 98,073
% Float 83.60%

Growth:

1-Year Return 97.98%
3-Year Return 48.43%
5-Year Return 503.19%
5-Year Revenue Growth 603.66%
5-Year Earnings Growth 1,516.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.27 on 02/23/21
Next Earnings Date 02/08/21
Earnings Per Share ttm 0.85
EPS Growth vs. Prev Qtr 17.65%
EPS Growth vs. Prev Year -16.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

CORT Ratios

Ratio
Price/Earnings ttm 28.06
Price/Earnings forward 24.06
Price/Earnings to Growth 2.30
Return-on-Equity % 22.60%
Return-on-Assets % 20.69%
Profit Margin % 29.96
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 7.91
Price/Cash Flow 25.30
Price/Book 5.42
Book Value/Share 4.50
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar